Cancer immunotherapy using RNA-loaded dendritic cells

Clinical and Experimental Immunology

Volumn 134, Issue 3, 2003, Pages 378-384

  Ponsaerts, P ^a,b   Van Tendeloo, V F I ^a   Berneman, Z N ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Dendritic cells; Electroporation; Immunotherapy, RNA; T cells

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RNA;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; DENDRITIC CELL; ELECTROPORATION; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE CLONE; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION; VIRUS IMMUNITY;

ANTIGENS, NEOPLASM; DENDRITIC CELLS; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; RNA, MESSENGER;

EID: 0346751949     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02286.x     Document Type: Review

References (41)

1. Van Tendeloo VFI, Van Broeckhoven C, Berneman ZN. Gene-based cancer vaccines: an ex vivo approach. Leukemia 2001; 15:545-58.
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
3. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8 (+) regulatory T cells in vivo in humans. Blood 2002; 100:174-7.
4. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25 (+) regulatory T cells convey suppressor activity to conventional CD4 (+) T helper cells. J Exp Med 2002; 196:255-60.
5. + monocyte-derived dendritic cells and implications for cancer vaccines. Crit Rev Immunol 2001; 21:157-78.
6. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99:351-8.
7. Lardon F, Snoeck HW, Berneman ZN et al. Generation of dendritic cells from bone marrow progenitors using GM-CSF, TNF-α, and additional cytokines: antagonistic effects of IL-4 and IFN-γ and selective involvement of TNF-α receptor-1. Immunology 1997; 91:553-9.
8. + hematopoietic progenitor cells toward distinct dendritic cell subsets of the Birbeck granule and MIIC-positive Langerhans cell and the interdigitating dendritic cell type. Blood 1996; 88:2541-8.
9. Romani N, Gruner S, Brang D et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180:83-93.
10. Zhou Y, Bosch ML, Salgaller ML. Current methods for loading dendritic cells with tumor antigen for induction of antitumor immunity. J Immunother 2002; 25:289-303.
11. Thurner B, Haendle I, Röder C et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 11:1669-78.
12. Santin AD, Hermonat PL, Ravaggi A et al. Induction of human papillomavirus-specific CD4 (+) and CD8 (+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer. J Virol 1999; 3:5402-10.
13. Herr W, Ranieri E, Olson W, Zarour H, Gesualdo L, Storkus WJ. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4 (+) and CD8 (+) T lymphocyte responses. Blood 2000; 96:1857-64.
14. Schott M, Feldkamp J, Schattenberg D et al. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrin 2000; 142:300-6.
15. Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6:332-6.
16. Kirk CJ, Mulé JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000; 11:797-806.
17. Jenne L, Schuler G, Steinkasserer A. Viral vectors for dendritic cell-based immunotherapy. Trends Immunol 2001; 22:102-7.
18. Van Tendeloo VFI, Snoeck HW, Lardon F et al. Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells. Gene Ther 1998; 5:700-7.
19. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72.
20. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186:1177-82.
21. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16:364-9.
22. Strobel I, Berchtold S, Gotze A, Schulze U, Schuler G, Steinkasserer A. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes. Gene Ther 2000; 7:2028-35.
23. Van Tendeloo V, Ponsaerts P, Lardon F et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells. Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98:49-56.
24. Ponsaerts P, Van Tendeloo VFI, Cools N et al. mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation. Leukemia 2002; 16:1324-30.
25. Sæbøe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Meth 2002; 259:191-203.
26. Kalady MF, Onaitis MW, Padilla KM, Emani S, Tylor DS, Pruitt SK. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. J Surg Res 2002; 105:17-24.
27. Lundqvist A, Noffz G, Pavlenko M et al. Nonviral and viral gene transfer into different subsets of human dendritic cells yield comparable efficiency of transfection. J Immunother 2002; 25:445-54.
28. Van Meirvenne S, Straetman L, Heirman C et al. Efficient genetic modifications of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9:787-97.
29. + T helper and a T killer cell. Nature 1998; 393:474-8.
30. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR. Help for cytotoxic-T cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80.
31. + T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002; 62:5041-8.
32. Thornburg C, Boczkowski D, Gilboa E, Nair SK. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervival cancer immunotherapy. J Immunother 2000; 23:412-8.
33. Heiser H, Dahm P, Yancey DR et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000; 164:5508-14.
34. Weissman D, Ni HP, Scales D et al. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 2000; 165:4710-7.
35. Ponsaerts P, Van den Bosch G, Cools N et al. Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol 2002; 169:1669-75.
36. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001; 61:3388-93.
37. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34.
38. Heiser A, Maurice MA, Yancey DR et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 2001; 166:2953-60.
39. Milazzo C, Reichardt VL, Müller MR, Grünebach F, Brossart P. Induction of myeloma specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2002; 101:977-82.
40. Heiser A, Coleman DM, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2001; 109:409-17.
41. Nair SK, Morse M, Boczkowski D et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235:540-9.